New York, New York--(Newsfile Corp. - January 17, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance") between November 25, 2019 and October 11, 2021.
If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/revance-therapeutics-inc-loss-submission-form?prid=22112&wire=5
Allegations against RVNC include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) quality control deficiencies existed at the Company's manufacturing facility for DaxibotulinumtoxinA for Injection ("DAXI"); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration ("FDA") would approve the DAXI Biologics License Application ("BLA") in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you suffered a loss in Revance you have until February 8, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/110440
